HC Wainwright Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 464.97% from the company’s current price.

ARTV has been the topic of several other reports. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Cantor Fitzgerald cut their price target on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a report on Tuesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $20.40.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $3.54 on Wednesday. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31. The stock’s fifty day moving average price is $4.78 and its 200-day moving average price is $9.29.

Institutional Trading of Artiva Biotherapeutics

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets purchased a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. purchased a new stake in Artiva Biotherapeutics during the 4th quarter valued at $52,000. Wells Fargo & Company MN lifted its holdings in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock valued at $87,000 after buying an additional 3,361 shares during the period. MetLife Investment Management LLC purchased a new position in shares of Artiva Biotherapeutics in the 3rd quarter worth $135,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Artiva Biotherapeutics in the third quarter worth $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.